Pandora Wealth Inc. Takes Position in Pulse Biosciences, Inc (NASDAQ:PLSE)

Key Points

• Pandora Wealth Inc. acquired a new stake in Pulse Biosciences, purchasing 51,452 shares valued at approximately $828,000.
• Oppenheimer initiated coverage on Pulse Biosciences, setting an "outperform" rating with a target price of $22.00 per share.
• The company's shares opened at $14.71, with a 52-week low of $13.77 and a high of $25.00.

Pandora Wealth Inc. purchased a new stake in shares of Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 51,452 shares of the company's stock, valued at approximately $828,000. Pandora Wealth Inc. owned approximately 0.08% of Pulse Biosciences as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Farther Finance Advisors LLC boosted its holdings in Pulse Biosciences by 24.6% in the first quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock worth $143,000 after purchasing an additional 1,778 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Pulse Biosciences by 15.1% in the fourth quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock worth $19,958,000 after purchasing an additional 150,506 shares in the last quarter. Deutsche Bank AG boosted its holdings in Pulse Biosciences by 65.1% in the fourth quarter. Deutsche Bank AG now owns 16,795 shares of the company's stock worth $292,000 after purchasing an additional 6,625 shares in the last quarter. Barclays PLC lifted its position in Pulse Biosciences by 8.5% during the 4th quarter. Barclays PLC now owns 32,881 shares of the company's stock worth $573,000 after acquiring an additional 2,575 shares during the last quarter. Finally, Rhumbline Advisers lifted its position in Pulse Biosciences by 6.3% during the 1st quarter. Rhumbline Advisers now owns 27,375 shares of the company's stock worth $440,000 after acquiring an additional 1,614 shares during the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Oppenheimer began coverage on shares of Pulse Biosciences in a research report on Monday, July 7th. They set an "outperform" rating and a $22.00 target price for the company.

Insiders Place Their Bets

In related news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction dated Thursday, June 12th. The shares were sold at an average price of $16.40, for a total value of $246,000.00. Following the sale, the chief technology officer owned 137,872 shares of the company's stock, valued at $2,261,100.80. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 71.50% of the stock is currently owned by insiders.

Pulse Biosciences Stock Down 0.1%

Shares of PLSE opened at $14.71 on Friday. The company has a 50-day simple moving average of $15.57 and a 200-day simple moving average of $17.04. Pulse Biosciences, Inc has a 52 week low of $13.77 and a 52 week high of $25.00.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.